EGFR and non-small cell lung carcinoma: However, double-dose osimertinib (160 mg/QD) (46) demonstrated a PFS of 6.8 months and an ORR of 28% in 25 NSCLC patients with advanced EGFR ex20ins mutations with common adverse events (AEs), including diarrhea, malaise, and skin dryness.